Key terms
About ATOS
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATOS news
Sep 10
8:37am ET
Atossa Therapeutics announces support of final rule from FDA
Sep 02
8:58am ET
Atos Shares Drop on Reduced Financial Targets
Aug 28
8:32am ET
Atossa Therapeutics granted U.S. patent for endoxifen
Aug 21
8:33am ET
Atossa, Quantum Health announce first patient dosed first patient in I-SPY 2
Aug 20
8:42am ET
Atossa announces appointment of Parks as VP, Investor, Public Relations
Aug 13
1:06pm ET
Atossa Therapeutics: A Promising Buy in Oncology with Strong Financials and Upcoming Trial Milestones
Aug 12
4:18pm ET
Texas probes CenterPoint, Carlyle weighs Nobian sale: Monday Buzz
Aug 12
12:06pm ET
Texas probes CenterPoint, Starbucks in talks with Elliott: Morning Buzz
Aug 12
10:56am ET
Atossa Therapeutics: A Promising Buy Amid Anticipated Clinical Breakthroughs
Aug 12
8:34am ET
Atossa Therapeutics reports Q2 EPS (5c), consensus (6c)
Jul 02
4:18pm ET
Atossa Therapeutics appoints Heather Rees as CFO
Jun 28
10:35am ET
Atossa Therapeutics’ Promising Z-endoxifen Trial Data Backs Analyst’s Buy Recommendation
Jun 28
8:39am ET
Atossa announces updated protocol for trial of (Z)-Endoxifen with abemaciclib
Jun 17
8:37am ET
Atossa Therapeutics set to join Russell 3000 Index
No recent press releases are available for ATOS
ATOS Financials
Key terms
Ad Feedback
ATOS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATOS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
